A recently released report by the Pharmaceutical Research and Manufacturers of America (PhRMA) provides information about 97 new drugs and vaccines that are currently in the process of being tested for use towards the prevention or cure of HIV and AIDS.

These 97 medications include 23 vaccines and 54 antiviral drugs, all of which are currently in clinical trials or waiting for FDA approval.

“We are greatly encouraged by these critically important medicines and vaccines in development to treat and prevent HIV infection,” said Billy Tauzin, President and CEO of…

On November 6, the Food and Drug Administration (FDA) approved revised dosing recommendations for zidovudine (Retrovir), a major anti-HIV drug used in children.

The update allows for treatment to begin at four weeks of age, as long as children weigh at least 4 kilograms (8 lb 13 oz). Previously the FDA had recommended starting children on zidovudine at six weeks of age.

Zidovudine, also known as azidothymidine (AZT), was the first drug approved for use against HIV in 1987. It is used for treating both adults and children with HIV…

On October 6th, the U.S. Department of Health and Human Services was proud to announce the addition of the 100th antiretroviral drug to the President’s Emergency Plan for AIDS Relief (PEPFAR) program. PEPFAR is dedicated to the treatment, prevention, and care of individuals affected by the worldwide HIV/AIDS pandemic.

PEPFAR was founded in 2003 by the United States congress, and today remains the greatest commitment ever made by a single nation against one disease. In September 2009, PEPFAR had provided antiretroviral treatment to more than 2.1 million people with HIV/AIDS…